The Generic and Biosimilar Medicines Association Code of Practice was introduced on 1 March 2010.
Since then, GBMA members have consistently demonstrated ethical conduct in line with community and professional expectations, and in compliance with the principles of the Code.
Recognising that the Code must evolve in parallel with the environment in which its members operate and supported by member’s continued adherence to the Code requirements, educational event and non-price benefit reporting requirement was removed from the 4th edition of the Code, adopted in December 2015.
The Code, now in its 5th edition, effective June 2021, continues to describe expected high standards of conduct for its members, along with an established complaint handling process.
The GBMA believes the Code of Practice is appropriate for self-regulation of suppliers of generic and biosimilar medicines and recognises the unique environment in which its members operate.